Thought Leadership

市場動向レポート 無料ダウンロード

World Preview 2023: Pharma's Age of Uncertainty

The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up.  From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…

レポートライブラリ

World Preview 2023 Infographic

Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA's shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking…

H1 Round Up: The haves and the have-nots

Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…

ADA/EASL eBook

June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…

ASCO 2023 Round Up

The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…

Q1 2023 Round Up: And so it continues...

2022 was a rough year for much of the pharma sector, with limited M&A, IPO, and venture financing activity. With Q1 now over, are we expecting to see an improvement…

Quarter 1 Round up 2023 Infographic

Pharma has had a tough go of it over the past year, with limited M&A, IPO, and venture financing activity. As Q1 draws to a close, many are wondering if the sector is…

CROI 2023 article pack

Thanks to the forum it provides the Conference on Retroviruses and Opportunistic Infections (CROI) has helped to facilitate the accelerating progress in HIV and AIDS…